Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023029 · ClinicalTrials.gov registry record · Phase 1
A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT07023029 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 33 participants.
The verdict
NCT07023029, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Novo Nordisk is developing a new study medicine, Etavopivat, to treat individuals with sickle cell disease (SCD). The purpose of the study is to determine the effect of Etavopivat on the electrical activity of the heart in healthy participants. The study comprises two parts: Part A and Part B. Part A investigates the safety of a high dose of Etavopivat. In this phase, participants will receive either a single dose of Etavopivat or a placebo. Which treatment the participant gets is decided by chance. In Part B, participants will get four different treatments on four different occasions: Etavopivat in 2 different doses (the new medicine that cannot be prescribed), a dummy medicine (placebo), and an already approved medicine (moxifloxacin). The order of the 4 study medicines is decided by chance. There will be a break of 7 days between each treatment. For Part A, the study duration will be from 10 to 36 days, and for Part B, the study duration will be from 27 to 53 days.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Etavopivat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023029
The ClinicalTrials.gov registry entry for NCT07023029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07023029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07023029 about?
NCT07023029 is a clinical study titled "A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants". Novo Nordisk is developing a new study medicine, Etavopivat, to treat individuals with sickle cell disease (SCD). The purpose of the study is to determine the effect of Etavopivat on the electrical activity of the heart in healthy participants. The study comprises two parts: Part A and Part B. Part ...
What is the current status of trial NCT07023029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-06-09. Estimated completion is 2025-09-22.
What interventions are being tested in trial NCT07023029?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Etavopivat (DRUG).
Who is sponsoring clinical trial NCT07023029?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.